» Articles » PMID: 24914218

Substrate Binding Protein SBP2 of a Putative ABC Transporter As a Novel Vaccine Antigen of Moraxella Catarrhalis

Overview
Journal Infect Immun
Date 2014 Jun 11
PMID 24914218
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Moraxella catarrhalis is a common respiratory tract pathogen that causes otitis media in children and infections in adults with chronic obstructive pulmonary disease. Since the introduction of the pneumococcal conjugate vaccines with/without protein D of nontypeable Haemophilus influenzae, M. catarrhalis has become a high-priority pathogen in otitis media. For the development of antibacterial vaccines and therapies, substrate binding proteins of ATP-binding cassette transporters are important targets. In this study, we identified and characterized a substrate binding protein, SBP2, of M. catarrhalis. Among 30 clinical isolates tested, the sbp2 gene sequence was highly conserved. In 2 different analyses (whole-cell enzyme-linked immunosorbent assay and flow cytometry), polyclonal antibodies raised to recombinant SBP2 demonstrated that SBP2 expresses epitopes on the bacterial surface of the wild type but not the sbp2 mutant. Mice immunized with recombinant SBP2 showed significantly enhanced clearance of M. catarrhalis from the lung compared to that in the control group at both 25-μg and 50-μg doses (P < 0.001). We conclude that SBP2 is a novel, attractive candidate as a vaccine antigen against M. catarrhalis.

Citing Articles

Otitis media: recent advances in otitis media vaccine development and model systems.

Zahid A, Wilson J, Grice I, Peak I Front Microbiol. 2024; 15:1345027.

PMID: 38328427 PMC: 10847372. DOI: 10.3389/fmicb.2024.1345027.


Screening of immunogenic proteins and evaluation of vaccine candidates against Mycoplasma synoviae.

Zhang G, Han L, Li Z, Chen Y, Li Q, Wang S NPJ Vaccines. 2023; 8(1):121.

PMID: 37582795 PMC: 10427712. DOI: 10.1038/s41541-023-00721-y.


Prevalence of as a Nasal Flora among Healthy Kindergarten Children in Bhaktapur, Nepal.

Amatya N, Paudel G, Saud B, Wagle S, Shrestha V, Adhikari B Interdiscip Perspect Infect Dis. 2022; 2022:3989781.

PMID: 35378873 PMC: 8976674. DOI: 10.1155/2022/3989781.


A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges.

Perez A, Murphy T Hum Vaccin Immunother. 2017; 13(10):2322-2331.

PMID: 28853985 PMC: 5647992. DOI: 10.1080/21645515.2017.1356951.


A Cation-Binding Surface Protein as a Vaccine Antigen To Prevent Moraxella catarrhalis Otitis Media and Infections in Chronic Obstructive Pulmonary Disease.

Murphy T, Brauer A, Johnson A, Wilding G, Koszelak-Rosenblum M, Malkowski M Clin Vaccine Immunol. 2017; 24(9).

PMID: 28659326 PMC: 5585693. DOI: 10.1128/CVI.00130-17.


References
1.
Tanabe M, Atkins H, Harland D, Elvin S, Stagg A, Mirza O . The ABC transporter protein OppA provides protection against experimental Yersinia pestis infection. Infect Immun. 2006; 74(6):3687-91. PMC: 1479284. DOI: 10.1128/IAI.01837-05. View

2.
Murphy T, Brauer A, Grant B, Sethi S . Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med. 2005; 172(2):195-9. PMC: 2718466. DOI: 10.1164/rccm.200412-1747OC. View

3.
Holder R, Kirse D, Evans A, Peters T, Poehling K, Swords W . One third of middle ear effusions from children undergoing tympanostomy tube placement had multiple bacterial pathogens. BMC Pediatr. 2012; 12:87. PMC: 3475091. DOI: 10.1186/1471-2431-12-87. View

4.
Nowalk A, Gilmore Jr R, Carroll J . Serologic proteome analysis of Borrelia burgdorferi membrane-associated proteins. Infect Immun. 2006; 74(7):3864-73. PMC: 1489744. DOI: 10.1128/IAI.00189-06. View

5.
Casey J, Kaur R, Friedel V, E Pichichero M . Acute otitis media otopathogens during 2008 to 2010 in Rochester, New York. Pediatr Infect Dis J. 2013; 32(8):805-809. PMC: 3755474. DOI: 10.1097/INF.0b013e31828d9acc. View